GlassScriptPhysician profile
Jacqueline Chasko
NPI 1336864636
$1,482.89
in general payments reported to CMS, 2019-2025
14 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $49.47 · 2023: $736 · 2024: $549 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.15 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $349.42 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Abbvie INC. | $217.70 | 2023-2024 | |
| Genzyme Corporation | $187.60 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.66 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $105.40 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $91.85 | 2024 | Fasenra, Airsupra |
| Genentech USA, INC. | $73.80 | 2023 | Xolair |
| Optinose US, INC. | $70.34 | 2023-2024 | |
| Lilly USA, LLC | $59.69 | 2022-2023 | Mounjaro |
| Ars Pharmaceuticals Operations, INC. | $27.80 | 2025 | Neffy |
| Amgen INC. | $18.55 | 2022 | |
| Biocryst US Sales Co., LLC | $16.81 | 2023 | Orladeyo |
| Pfizer INC. | $15.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Chasko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.